Investigational drug · Phase 2
NDX-3324
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Eosinophilic Esophagitis.
Phase 2Last checked: Nov 19, 2026Latest source record: May 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "NDX-3324"
First trial start
2023
Jan 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NDX-3324", any sponsor or status.
Conditions studied
As listed on its trial records.
- Eosinophilic Esophagitis
Approved drugs for the same conditions: Eosinophilic esophagitis · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "NDX-3324" as an intervention, largest first.
NexEos Diagnostics, Inc.Industry
NCT05757856 · 34 participants · Start Jan 20, 2023 · Primary completion May 22, 2025
Drug: NDX-3315; NDX-3324 · For: Eosinophilic Esophagitis
Sites: Chicago, Illinois; Philadelphia, Pennsylvania; Salt Lake City, Utah
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Eosinophilic Esophagitis
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- cendakimabCC-93538, BMS-986355Phase 31 trial
Bristol Myers Squibb · Eosinophilic Esophagitis
- EP-104GIPhase 21 trial
Eupraxia Pharmaceuticals Inc. · Eosinophilic Esophagitis
- NDX-3315Phase 21 trial
NexEos Diagnostics, Inc. · Eosinophilic Esophagitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.